Has Sarena Richardson received payments from drug or device companies?

Yes. Drug and device makers reported $2,554 in general payments to Sarena Richardson across 122 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sarena Richardson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sarena Richardson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sarena Richardson

Primary Care · Slidell, LANPI 1144942624

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,056, 2.0 times the $520 reported in 2022.

$2,554in general payments, 2019–2025

Across 122 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$553
AstraZeneca$456
Lilly USA, LLC$275
Mylan Specialty L.p.$239
Exact Sciences$92
Phathom Pharmaceuticals, Inc.$90
plus $850 from 24 others

What the payments were for

Food & beverage$2,554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	25	$553
AstraZeneca	20	$456
Lilly USA, LLC	12	$275
Mylan Specialty L.p.	10	$239
Exact Sciences	5	$92
Phathom Pharmaceuticals, Inc.	6	$90
Pfizer	5	$89
Boehringer Ingelheim	4	$81
AbbVie	4	$79
Bayer	3	$75
GSK	4	$70
Xeris Pharmaceuticals, Inc.	2	$50
Coloplast	2	$49
Amneal Pharmaceuticals LLC	2	$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$32
Merck	2	$27
Dexcom, Inc.	1	$25
Axsome Therapeutics, Inc.	1	$25
Sumitomo Pharma America, Inc.	1	$23
Esperion Therapeutics, Inc.	1	$22
Takeda Pharmaceuticals U.S.A., Inc.	1	$20
Otsuka America Pharmaceutical, Inc.	1	$19
Inspire Medical Systems, Inc.	1	$19
Seqirus USA Inc	1	$19
Amgen	1	$18
VBI Vaccine (delaware) Inc.	1	$16
Kowa Pharmaceuticals America, Inc.	1	$14
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$14
Lundbeck LLC	1	$14
Biohaven Pharmaceutical Holding Company Ltd.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,554 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Valsartan	18	$235
Atorvastatin Calcium	28	$119

Paid to pharmacies, not to this prescriber.